Browse > Article
http://dx.doi.org/10.15324/kjcls.2018.50.4.449

Diagnostic Availability of Estrogen Receptor Alpha mRNA on Cervical Cancer Tissue  

Kim, Geehyuk (Department of Biomedical Laboratory Science, College of Health Sciences, Yonsei University)
Yu, Kwangmin (Department of Biomedical Laboratory Science, College of Health Sciences, Yonsei University)
Kim, Jungho (Department of Biomedical Laboratory Science, College of Health Sciences, Yonsei University)
Kim, Seoyong (Department of Biomedical Laboratory Science, College of Health Sciences, Yonsei University)
Park, Sunyoung (Department of Biomedical Laboratory Science, College of Health Sciences, Yonsei University)
Ahn, Sungwoo (Department of Biomedical Laboratory Science, College of Health Sciences, Yonsei University)
Lee, Ji-Young (Department of Biomedical Laboratory Science, College of Health Sciences, Yonsei University)
Kim, Sunghyun (Department of Clinical Laboratory Science, College of Health Sciences, Catholic University of Pusan)
Park, Ho-Hyun (Department of Biomedical Laboratory Science, Mokpo Science University)
Lee, Dongsup (Department of Clinical Laboratory Science, Hyejeon College)
Publication Information
Korean Journal of Clinical Laboratory Science / v.50, no.4, 2018 , pp. 449-456 More about this Journal
Abstract
Cervical cancer is the fourth most frequently diagnosed cancer in women worldwide. In lower Human Development Index countries, it has the second highest incidence and mortality among cancer in women. Therefore, better diagnosis and treatment systems are needed. Among them, estrogen receptor alpha ($ER-{\alpha}$) mRNA expression has been analyzed with RT-qPCR since several studies reported that $ER-{\alpha}$ is necessary in the maturation of the uterus and is related to cervical cancer. In this study, $ER-{\alpha}$ quantitative analysis was performed on various lesions and normal tissue samples. Based on the receiver operating characteristic (ROC) curve, its sensitivity and specificity were 85% and 75%, respectively, showing higher or similar results to those of conventional HPV tests. In addition, its expression level was analyzed with clinical information. With regression analysis, the R square value between the $ER-{\alpha}$ mRNA expression level and menopause status was 0.5041, indicating a strong correlation. This study was performed as part of a pilot study and suggests that $ER-{\alpha}$ is related to carcinogenesis. Future studies will examine other hormones and menopausal factors with a larger sample size.
Keywords
Age; Cervical cancer; Estrogen receptor alpha; Formalin-fixed paraffin-embedded tissue; Menopause;
Citations & Related Records
Times Cited By KSCI : 2  (Citation Analysis)
연도 인용수 순위
1 Schneider A, Hommel G, Blettner M. Linear regression analysis:part 14 of a series on evaluation of scientific publications. Dtsch Arztebl Int. 2010;107:776-782. https://doi.org/10.3238/arztebl.2010.0776.
2 Zhai Y, Bommer GT, Feng Y, Wiese AB, Fearon ER, Cho KR. Loss of estrogen receptor 1 enhances cervical cancer invasion. Am J Pathol. 2010;177: 884-895. https://doi.org/10.2353/ajpath.2010.091166.   DOI
3 Roura E, Travier N, Waterboer T, de Sanjose S, Bosch FX, Pawlita M, et al. The influence of hormonal factors on the risk of developing cervical cancer and pre-cancer: results from the EPIC cohort. PLoS One. 2016;11:e0147029. https://doi.org/10.1371/journal.pone.0147029.   DOI
4 Lau SK, Chu PG, Weiss LM. Immunohistochemical expression of estrogen receptor in pulmonary adenocarcinoma. Appl Immunohistochem Mol Morphol. 2006;14:83-87. https://doi.org/ 10.1097/01.pai.0000168593.35850.9c.   DOI
5 Liu S, Semenciw R, Mao Y. Cervical cancer: the increasing incidence of adenocarcinoma and adenosquamous carcinoma in younger women. CMAJ. 2001;164:1151-1152.
6 van der Horst J, Siebers AG, Bulten J, Massuger LF, de Kok IM. Increasing incidence of invasive and in situ cervical adenocarcinoma in the Netherlands during 2004-2013. Cancer Med. 2017;6:416-423. https://doi.org/10.1002/cam4.971.   DOI
7 Moore DS, Notz WI, Flinger MA. The basic practice of statistics. 6th ed. New York: W. H. Freeman and company; 2013. p138.
8 Elson DA, Riley RR, Lacey A, Thordarson G, Talamantes FJ, Arbeit JM. Sensitivity of the cervical transformation zone to estrogen-induced squamous carcinogenesis. Cancer Res. 2000;60:1267-1275.
9 Shai A, Brake T, Somoza C, Lambert PF. The human papillomavirus E6 oncogene dysregulates the cell cycle and contributes to cervical carcinogenesis through two independent activities. Cancer Res. 2007;67:1626-1635.   DOI
10 Arbeit JM1, Howley PM, Hanahan D. Chronic estrogen-induced cervical and vaginal squamous carcinogenesis in human papillomavirus type 16 transgenic mice. Proc Natl Acad Sci U S A. 1996;93:2930-2935.   DOI
11 Giron RA, Montano LF, Escobar ML, Lopez-Marure R. Dehydroepiandrosterone inhibits the proliferation and induces the death of HPV-positive and HPV-negative cervical cancer cells through an androgen- and estrogen-receptor independent mechanism. FEBS J. 2009;276:5598-5609.   DOI
12 Chung SH, Franceschi S, Lambert PF. Estrogen and ER-${\alpha}$: culprits in cervical cancer?. Trends Endocrinol Metab. 2010;21:504-511.   DOI
13 Spurgeon ME, Chung SH, Lambert PF. Recurrence of cervical cancer in mice after selective estrogen receptor modulator therapy. Am J Pathol. 2014;184:530-540.   DOI
14 Hellberg D. Sex steroids and cervical cancer. Anticancer Res. 2012;32:3045-3054.
15 den Boon JA, Pyeon D, Wang SS, Horswill M, Schiffman M, Sherman M, et al. Molecular transitions from papillomavirus infection to cervical precancer and cancer: Role of stromal estrogen receptor signaling. Proc Natl Acad Sci U S A. 2015;112:E3255-264.   DOI
16 Moodley J. Combined oral contraceptives and cervical cancer. Curr Opin Obstet Gynecol. 2004;16:27-29.   DOI
17 de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. The Lancet Oncology. 2010;11, 1048-1056.   DOI
18 Gierisch JM, Coeytaux RR, Urrutia RP, Havrilesky LJ, Moorman PG, Lowery WJ, et al.. Oral contraceptive use and risk of breast, cervical, colorectal, and endometrial cancers: a systematic review. Cancer Epidemiol Biomarkers Prev. 2013;22:1931-1943.   DOI
19 Gheit T, Landi S, Gemignani F, Snijders PJ, Vaccarella S, Franceschi S, et al. Development of a sensitive and specific assay combining multiplex PCR and DNA microarray primer extension to detect high-risk mucosal human papillomavirus types. J Clin Microbiol. 2006;44:2025-2031.   DOI
20 Kitchener HC, Almonte M, Gilham C, Dowie R, Stoykova B, Sargent A, et al. ARTISTIC: a randomised trial of human papillomavirus (HPV) testing in primary cervical screening. Health Technol Assess. 2009;13:1-150, iii-iv.
21 Hellman K, Lindquist D, Ranhem C, Wilander E, Andersson S. Human papillomavirus, p16(INK4A), and Ki-67 in relation to clinicopathological variables and survival in primary carcinoma of the vagina. Br J Cancer. 2014;110:1561-1570.   DOI
22 Paterni I, Granchi C, Katzenellenbogen JA, Minutolo F. Estrogen receptors alpha ($ER{\alpha}$) and beta ($ER{\beta}$): subtype-selective ligands and clinical potential. Steroids. 2014;90:13-29.   DOI
23 Lee HR, Kim TH, Choi KC. Functions and physiological roles of two types of estrogen receptors, $ER{\alpha}$ and $ER{\beta}$, identified by estrogen receptor knockout mouse. Lab Anim Res. 2012;28:71-76.   DOI
24 Hess RA. Estrogen in the adult male reproductive tract: a review. Reprod Biol Endocrinol. 2003;9:1-52.
25 World Health Organization (WHO). Comprehensive cervical cancer control: a guide to essential practice. 2nd ed. 2014;9-40. [Internet]. Geneva: World Health Organization; 2018 [cited 2018 Nov 1]. Available from: http://www.who.int/reproductivehealth/publications/cancers/cervical-cancer-guide/en/.
26 Hong D, Lu W, Ye F, Hu Y, Xie X. Gene silencing of HPV16 E6/E7 induced by promoter-targeting siRNA in SiHa cells. Br j Cancer. 2009;101:1798-1804.   DOI
27 Benard VB, Watson M, Castle PE, Saraiya M. Cervical carcinoma rates among young females in the United States. Obstet Gynecol. 2012;120:1117-1123.
28 Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008:GLOBOCAN 2008. IJC. 2010;127:2893-2917. https://doi.org/10.1002/ijc.25516.
29 LaCour DE, Trimble C. Human papillomavirus in infants: transmission, prevalence, and persistence. J Pediatr Adolesc Gynecol. 2012;25: 93-97.   DOI
30 Koshiol J, Lindsay L, Pimenta JM, Poole C, Jenkins D, Smith JS. Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis. Am J Epidemiol. 2008;168:123-137.   DOI
31 Rao X, Huang X, Zhou Z, Lin X. An improvement of the 2^(-delta delta CT) method for quantitative real-time polymerase chain reaction data analysis. Biostat Bioinforma Biomath. 2013;3:71-85.
32 Shen K, Yueng W, Ngan H. Estrogen and progesterone receptors in normal cervix and primary cervical carcinoma. Chin Med J (Engl). 1994;107:648-652.
33 Kumar MM, Davuluri S, Poojar S, Mukherjee G, Bajpai AK, Bafna UD, et al. Role of estrogen receptor alpha in human cervical cancer-associated fibroblasts: a transcriptomic study. Tumour Biol. 2016;37:4409-4420. https://doi.org/10.1007/s13277-015-4257-6.   DOI
34 Park SY, Yoon HS, Bang HE, Kim Y, Choi SK, Ahn SW, et al. Analytical performance of sensitivity and specificity for rapid multiplex high risk human papillomavirus detection kit: HPV ViroCheck. Korean J Clin Lab Sci. 2017;49:446-454. https://doi.org/10.15324/kjcls.2017.49.4.446.   DOI
35 Kim G, Cho H, Lee D, Park S, Lee J, Wang HY, et al. Comparison of FFPE historical versus LBP cytological samples for HPV detection and typing in cervical cancer. Exp Mol Pathol. 2017;102:321-326. https://doi.org/ 10.1016/j.yexmp.2017.02.015.   DOI
36 Barut MU, Kale A, Kuyumcuoglu U, Bozkurt M, Agacayak E, Ozekinci S, et al. Analysis of sensitivity, specificity, and positive and negative predictive values of smear and colposcopy in diagnosis of premalignant and malignant cervical lesions. Med Sci Monit. 2015;21:3860-3867. https://doi.org/10.12659/MSM.895227.   DOI
37 Benevolo M, Vocaturo A, Caraceni D, French D, Rosini S, Zappacosta R, et al. Sensitivity, specificity, and clinical value of human papillomavirus (HPV) E6/E7 mRNA assay as a triage test for cervical cytology and HPV DNA test. J Clin Microbiol. 2011;49:2643-2650. . https://doi.org/10.1128/JCM.02570-10.   DOI
38 Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;0:1-31.
39 Radley D, Saah A, Stanley M. Persistent infection with human papillomavirus 16 or 18 is strongly linked with high-grade cervical disease. Hum Vaccin Immunother. 2016;12:768-772. https://doi.org/ 10.1080/21645515.2015.1088616.   DOI
40 Ferenczy A, Franco E. Persistent human papillomavirus infection and cervical neoplasia. Lancet Oncol. 2002;3:11-16. https://doi.org/10.1016/S1470-2045(01)00617-9.   DOI
41 Kim IK, Choi HM, Kim MH. Menopausal knowledge and management in peri-menopausal women. J Korean Soc Menopause. 2012;18:124-131. https://doi.org/10.6118/jksm.2012.18.2.124.   DOI
42 Lee KH, Che SC. Introduction to partial least square: common criteria and practical considerations. Adv Mater Res. 2013;779-780:1766-1769. https://doi.org/10.4028/www.scientific.net/AMR.779-780.1766.   DOI
43 Goodman A. HPV testing as a screen for cervical cancer. BMJ. 2015;350:h2372.   DOI
44 Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12-19.   DOI
45 Franco EL, Duarte-Franco E, Ferenczy A. Cervical cancer: epidemiology, prevention and the role of human papillomavirus infection. CMAJ. 2001;164:1017-1025.
46 Park SY, Wang HY, Kim SH, Kim GH, Bong SY, Jang HS, et al. Performance of HPV E6/E7 mRNA genotyping test on paired cervical. Biomedical Science Letters. 2016;22:98-106.   DOI
47 Riley RR, Duensing S, Brake T, Munger K, Lambert PF, Arbeit JM. Dissection of human papillomavirus E6 and E7 function in transgenic mouse models of cervical carcinogenesis. Cancer Res. 2003;63:4862-4871.